TABLE 3.
Comparison between responders and nonresponders at rituximab initiation.
| Variables | Responders (N = 7) | Nonresponders (N = 28) | P-Valve |
|---|---|---|---|
| Demographics | |||
| Gender (male/female) | 6/1 | 24/3 | 0.855 |
| Age (year) | 53.00 (42.50, 59.00) | 55.50 (50.25, 68.25) | 0.708 |
| BP (mmHg) | |||
| Systolic | 132.43 ±7.99 | 130.46 ± 11.18 | 0.667 |
| Diastolic | 81.71 ± 6.34 | 78.69 ± 9.17 | 0.421 |
| Serum creatinine (µmol/L) | 171.00 (161.50, 209.50) | 140.00 (133.00, 217.00) | 0.672 |
| eGFR (ml/min/1.73m2) | 29.03 (28.76, 35.07) | 45.09 (26.13, 53.75) | 0.835 |
| 24 h urinary protein (g/d) | 7.92 (4.19, 14.00) | 11.21 (5.22, 13.35) | 0.624 |
| Albumin (g/L) | 23.30 (20.20, 29.25) | 19.90 (16.40, 23.80) | 0.183 |
| CD19, per mm | 241.00 (165.50, 249.50) | 166.50 (80.00, 278.00) | 0.800 |
| CD4, per mm | 1,059.00 (945.00, 1,315.00) | 812.50 (522.50, 962.00) | 0.317 |
| Median time since biopsy-proven diagnosis (month) | 30.00 (15.50, 39.00) | 35.50 (16.00, 54.00) | 0.559 |
| anti- PLA2R-Ab titer (RU/mL) | 5.90 (5.70, 34.20) | 71.80 (45.40, 257.90) | 0.531 |
| Diuretics (N, %) | 0 (0.0%) | 7 (25.0%) | 0.176 |
| ACE inhibitor or ARB (N, %) | 0 (0.0%) | 2 (7.1%) | 0.635 |
| Statins (N, %) | 2 (28.6%) | 13 (46.4%) | 0.340 |
| Number (%) of patients with | |||
| Zero round of immunomeds | 1 (14.3%) | 2 (7.1%) | 0.778 |
| One round of immunomeds | 4 (57.1%) | 15 (53.6%) | |
| Two rounds of immunomeds | 2 (28.6%) | 8 (28.6%) | |
| Three rounds of immunomeds | 0 (0.0%) | 3 (10.7%) | |
| rituximab dose (g) | 2.00 (1.20, 2.00) | 2.00 (2.00, 2.00) | 0.294 |
Data presented as median (first-third interquartile range) or mean ± SD, or number (percentage). *Stands for p < 0.05. BP, blood pressure; eGFR, estimated glomerular filtration rate; CD, cluster of differentiation; anti- PLA2R-Ab, anti-phospholipase A2 receptor antibody; ACE inhibitor, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker.